» Articles » PMID: 29092098

Differentiated and Anaplastic Thyroid Carcinoma: Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual

Overview
Publisher Wiley
Specialty Oncology
Date 2017 Nov 2
PMID 29092098
Citations 158
Authors
Affiliations
Soon will be listed here.
Abstract

Answer questions and earn CME/CNE This is a review of the major changes in the American Joint Committee on Cancer staging manual, eighth edition, for differentiated and anaplastic thyroid carcinoma. All patients younger than 55 years have stage I disease unless they have distant metastases, in which case, their disease is stage II. In patients aged 55 years or older, the presence of distant metastases confers stage IVB, while cases without distant metastases are further categorized based on the presence/absence of gross extrathyroidal extension, tumor size, and lymph node status. Patients aged 55 years or older whose tumor measures 4 cm or smaller (T1-T2) and is confined to the thyroid (N0, NX) have stage I disease, and those whose tumor measures greater than 4 cm and is confined to the thyroid (T3a) have stage II disease regardless of lymph node status. Patients aged 55 years or older whose tumor is confined to the thyroid and measures 4 cm or smaller (T1-T2) with any lymph node metastases present (N1a or N1b) have stage II disease. In patients who demonstrate gross extrathyroidal extension, the disease is considered stage II if only the strap muscles are grossly invaded (T3b); stage III if there is gross invasion of the subcutaneous tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve (T4a); or stage IVA if there is gross invasion of the prevertebral fascia or tumor encasing the carotid artery or internal jugular vein (T4b). The same T definitions will be used for both differentiated and anaplastic thyroid cancer, but the basic premise of the anatomic stage groups will remain the same. CA Cancer J Clin 2018;68:55-63. © 2017 American Cancer Society.

Citing Articles

Postoperative quality of life in patients treated for thyroid cancer with transoral endoscopic and open surgery.

Wu X, Liu H, He J, Hu C, Xie W, Luo B Sci Rep. 2025; 15(1):7257.

PMID: 40025116 PMC: 11873165. DOI: 10.1038/s41598-025-91291-7.


Nomogram Predicting Progression-Free Survival in Locally Advanced Papillary Thyroid Cancer with Recurrent Laryngeal Nerve Invasion.

Song Y, Ning Y, Li H, He Y, Liu Y, Liu S J Otolaryngol Head Neck Surg. 2025; 54:19160216251314750.

PMID: 39945284 PMC: 11822831. DOI: 10.1177/19160216251314750.


Age-stratified deep learning model for thyroid tumor classification: a multicenter diagnostic study.

Zou W, Zhou Y, Yao J, Feng B, Xiong D, Chen C Eur Radiol. 2025; .

PMID: 39903238 DOI: 10.1007/s00330-025-11386-7.


Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study.

Kanbayashi Y, Kaneko Y, Kobayashi M, Wakabayashi H, Shimizu T, Uchida M In Vivo. 2024; 39(1):346-352.

PMID: 39740919 PMC: 11705116. DOI: 10.21873/invivo.13834.


Development and validation of a risk score model for patient stratification and personalized management of papillary thyroid cancer.

Guo H, Shen N, Hu Y, Hao X, Zhang H, Huang T Gland Surg. 2024; 13(11):2116-2127.

PMID: 39678428 PMC: 11635556. DOI: 10.21037/gs-24-344.


References
1.
Kim S, Myong J, Suh H, Lee K, Youn Y . Optimal Cutoff Age for Predicting Mortality Associated with Differentiated Thyroid Cancer. PLoS One. 2015; 10(6):e0130848. PMC: 4477980. DOI: 10.1371/journal.pone.0130848. View

2.
Woo C, Sung C, Choi Y, Kim W, Kim T, Shong Y . Clinicopathological Significance of Minimal Extrathyroid Extension in Solitary Papillary Thyroid Carcinomas. Ann Surg Oncol. 2015; 22 Suppl 3:S728-33. PMC: 4686556. DOI: 10.1245/s10434-015-4659-0. View

3.
Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl D, Bidart J . Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005; 90(10):5723-9. DOI: 10.1210/jc.2005-0285. View

4.
Ghossein R . Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med. 2009; 133(5):683-91. DOI: 10.5858/133.5.683. View

5.
Ito Y, Ichihara K, Masuoka H, Fukushima M, Inoue H, Kihara M . Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg. 2010; 34(11):2570-80. DOI: 10.1007/s00268-010-0710-2. View